US6982260B1
(en)
|
1999-11-22 |
2006-01-03 |
Warner-Lambert Company |
Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
|
US7235551B2
(en)
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
BR0114829A
(en)
|
2000-10-23 |
2003-09-23 |
Smithkline Beecham Corp |
novel compounds |
RU2004133811A
(en)
|
2002-04-19 |
2005-04-20 |
Смитклайн Бичам Корпорейшн (US) |
new connections |
CA2486376A1
(en)
|
2002-05-22 |
2003-12-04 |
Amgen Inc. |
Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
|
JP4555082B2
(en)
|
2002-08-08 |
2010-09-29 |
アムジエン・インコーポレーテツド |
Vanilloid receptor ligands and their use in therapy
|
SI1648889T1
(en)
*
|
2003-07-11 |
2009-02-28 |
Warner Lambert Co |
Isethionate salt of a selective cdk4 inhibitor
|
SG145695A1
(en)
|
2003-07-29 |
2008-09-29 |
Xenon Pharmaceuticals Inc |
Pyridyl derivatives and their use as therapeutic agents
|
PT1648874E
(en)
|
2003-07-30 |
2011-12-23 |
Xenon Pharmaceuticals Inc |
Piperazine derivatives and their use as therapeutic agents
|
US20050113398A1
(en)
*
|
2003-08-07 |
2005-05-26 |
Ankush Argade |
2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
|
EP1670794A2
(en)
|
2003-09-30 |
2006-06-21 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
MY139645A
(en)
|
2004-02-11 |
2009-10-30 |
Amgen Inc |
Vanilloid receptor ligands and their use in treatments
|
JP2007522233A
(en)
|
2004-02-11 |
2007-08-09 |
アムジエン・インコーポレーテツド |
Vanilloid receptor ligands and their use in therapy
|
JP2007530654A
(en)
*
|
2004-03-30 |
2007-11-01 |
ファイザー・プロダクツ・インク |
Signal transduction inhibitor combinations
|
WO2005099711A1
(en)
*
|
2004-04-13 |
2005-10-27 |
Icagen, Inc. |
Polycyclic pyrimidines as potassium ion channel modulators
|
EP1789413A1
(en)
|
2004-09-13 |
2007-05-30 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
CN101083982A
(en)
|
2004-09-20 |
2007-12-05 |
泽农医药公司 |
Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
|
AU2005286648A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
|
AU2005286728A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
|
US7777036B2
(en)
|
2004-09-20 |
2010-08-17 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as therapeutic agents
|
US7829712B2
(en)
|
2004-09-20 |
2010-11-09 |
Xenon Pharmaceuticals Inc. |
Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
|
CA2580855A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
|
CN101083993A
(en)
|
2004-09-20 |
2007-12-05 |
泽农医药公司 |
Heterocyclic derivatives and their use as therapeutic agents
|
WO2006047492A2
(en)
|
2004-10-22 |
2006-05-04 |
Amgen Inc. |
Substituted nitrogen-containing heterocycles as vanilloid receptor ligands and their uses as medicament
|
CA2577588C
(en)
*
|
2004-10-29 |
2013-09-10 |
Tibotec Pharmaceuticals Ltd. |
Hiv inhibiting bicyclic pyrimidine derivatives
|
WO2006074985A1
(en)
|
2005-01-14 |
2006-07-20 |
Janssen Pharmaceutica N.V. |
5-membered annelated heterocyclic pyrimidines as kinase inhibitors
|
AU2006205850A1
(en)
*
|
2005-01-18 |
2006-07-20 |
Janssen Pharmaceutica N.V. |
Pyrazolopyrimidines as cell cycle kinase inhibitors
|
US7301022B2
(en)
|
2005-02-15 |
2007-11-27 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
PE20061193A1
(en)
*
|
2005-03-25 |
2006-12-02 |
Glaxo Group Ltd |
DERIVATIVES 3,4-dihydropyrimido [4,5-d] pyrimidine-2- [1H] -0NA AS p38 KINASE INHIBITORS |
US7479558B2
(en)
*
|
2005-03-25 |
2009-01-20 |
Glaxo Group Limited |
Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives
|
MY145281A
(en)
|
2005-03-25 |
2012-01-13 |
Glaxo Group Ltd |
Novel compounds
|
US20090137550A1
(en)
*
|
2005-03-25 |
2009-05-28 |
Glaxo Group Limited |
Novel Compounds
|
WO2007130075A1
(en)
|
2005-06-03 |
2007-11-15 |
Xenon Pharmaceuticals Inc. |
Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
|
GB0512844D0
(en)
*
|
2005-06-23 |
2005-08-03 |
Novartis Ag |
Organic compounds
|
EP2004641B1
(en)
|
2006-03-30 |
2010-09-29 |
Tibotec Pharmaceuticals |
Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines
|
TW200808739A
(en)
|
2006-04-06 |
2008-02-16 |
Novartis Vaccines & Diagnostic |
Quinazolines for PDK1 inhibition
|
AR060635A1
(en)
*
|
2006-04-27 |
2008-07-02 |
Banyu Pharma Co Ltd |
I derived from 1,2-dihydro-3H-pyrazolo [3,4-d] pyrimidin-3-one, pharmaceutical compositions comprising them and their use in the treatment of cancer |
CA2651072A1
(en)
*
|
2006-05-01 |
2007-11-08 |
Pfizer Products Inc. |
Substituted 2-amino-fused heterocyclic compounds
|
WO2008016547A2
(en)
*
|
2006-07-31 |
2008-02-07 |
Praecis Pharmaceuticals Incorporated |
Aurora kinase inhibitors from an encoded small molecule library
|
WO2008016675A1
(en)
|
2006-08-01 |
2008-02-07 |
Praecis Pharmaceuticals Incorporated |
P38 kinase inhibitors
|
MX337906B
(en)
|
2006-10-19 |
2016-03-28 |
Signal Pharm Llc |
Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors.
|
CA2673965A1
(en)
*
|
2006-12-28 |
2008-07-10 |
Taisho Pharmaceutical Co., Ltd. |
Pyrazolopyrimidine compound
|
GB0706632D0
(en)
*
|
2007-04-04 |
2007-05-16 |
Cyclacel Ltd |
New purine derivatives
|
WO2008132505A1
(en)
*
|
2007-04-27 |
2008-11-06 |
Astrazeneca Ab |
N' - (phenyl) -n- (morpholin-4-yl-pyridin-2-yl) -pyrimidine-2, 4-diamine derivatives as ephb4 kinase inhibitors for the treatment of proliferative conditions
|
CA2685588A1
(en)
*
|
2007-06-08 |
2008-12-11 |
Bayer Cropscience Sa |
Fungicide heterocyclyl-pyrimidinyl-amino derivatives
|
WO2009071535A1
(en)
*
|
2007-12-03 |
2009-06-11 |
Boehringer Ingelheim International Gmbh |
Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
|
CN101945867A
(en)
|
2007-12-19 |
2011-01-12 |
安姆根有限公司 |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
WO2009126584A1
(en)
|
2008-04-07 |
2009-10-15 |
Amgen Inc. |
Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
|
CN102118968A
(en)
|
2008-06-10 |
2011-07-06 |
雅培制药有限公司 |
Novel tricyclic compounds
|
GB0812969D0
(en)
|
2008-07-15 |
2008-08-20 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
ME01282B
(en)
*
|
2008-08-22 |
2013-06-20 |
Novartis Ag |
Pyrrolopyrimidine compounds as cdk inhibitors
|
US8110578B2
(en)
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
WO2010061971A1
(en)
*
|
2008-11-28 |
2010-06-03 |
興和株式会社 |
Pyridine-3-carboxyamide derivative
|
AU2009334869A1
(en)
|
2008-12-29 |
2011-07-14 |
Fovea Pharmaceuticals |
Substituted quinazoline compounds
|
NZ594508A
(en)
|
2009-02-13 |
2013-12-20 |
Fovea Pharmaceuticals |
[1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
|
EP2414361A1
(en)
|
2009-03-31 |
2012-02-08 |
ArQule, Inc. |
Substituted heterocyclic compounds
|
JP2012526850A
(en)
|
2009-05-13 |
2012-11-01 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルThe University Of North Carolina At Chapel Hill |
Cyclin-dependent kinase inhibitors and uses thereof
|
CA2764818A1
(en)
*
|
2009-06-08 |
2010-12-16 |
California Capital Equity, Llc |
Triazine derivatives and their therapeutical applications
|
ES2444777T3
(en)
|
2009-06-12 |
2014-02-26 |
Bristol-Myers Squibb Company |
Nicotinamide compounds useful as kinase modulators
|
KR20120091240A
(en)
|
2009-10-26 |
2012-08-17 |
시그날 파마소티칼 엘엘씨 |
Methods of synthesis and purification of heteroaryl compounds
|
ES2637588T3
(en)
|
2009-12-01 |
2017-10-13 |
Abbvie Inc. |
New tricyclic compounds
|
CN102711470A
(en)
|
2009-12-01 |
2012-10-03 |
雅培制药有限公司 |
Novel tricyclic compounds
|
UY33227A
(en)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Pyrrolopyrimidine compounds as inhibitors of CDK4 / 6 |
GB201007286D0
(en)
|
2010-04-30 |
2010-06-16 |
Astex Therapeutics Ltd |
New compounds
|
WO2011156698A2
(en)
|
2010-06-11 |
2011-12-15 |
Abbott Laboratories |
NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
|
TW201204723A
(en)
|
2010-06-22 |
2012-02-01 |
Fovea Pharmaceuticals |
Heterocyclic compounds, their preparation and their therapeutic application
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
EP2955183A1
(en)
|
2010-10-25 |
2015-12-16 |
G1 Therapeutics, Inc. |
Cdk inhibitors
|
CN103501789A
(en)
|
2010-11-17 |
2014-01-08 |
北卡罗来纳大学查珀尔希尔分校 |
Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6
|
GB201020179D0
(en)
|
2010-11-29 |
2011-01-12 |
Astex Therapeutics Ltd |
New compounds
|
CA2817460A1
(en)
|
2010-12-17 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
ES2620521T3
(en)
|
2011-03-23 |
2017-06-28 |
Amgen Inc. |
Dual condensed tricyclic inhibitors of CDK 4/6 and FLT3
|
NZ614776A
(en)
|
2011-04-22 |
2015-06-26 |
Signal Pharm Llc |
Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
|
WO2013059396A2
(en)
|
2011-10-19 |
2013-04-25 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with tor kinase inhibitors
|
GB201118652D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
GB201118675D0
(en)
*
|
2011-10-28 |
2011-12-14 |
Astex Therapeutics Ltd |
New compounds
|
GB201118656D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
GB201118654D0
(en)
|
2011-10-28 |
2011-12-07 |
Astex Therapeutics Ltd |
New compounds
|
ES2694413T3
(en)
|
2011-12-02 |
2018-12-20 |
Signal Pharmaceuticals, Llc |
Pharmaceutical compositions of 7- (6- (2-hydroxypropan-2-yl) pyridin-3-yl) -1 - ((trans) -4-methoxycyclohexyl) -3,4-dihydropyrazino [2,3-b] pyrazine- 2 (1H) -one, a solid form thereof and methods for its use
|
CN104169275B
(en)
*
|
2012-01-13 |
2017-06-09 |
百时美施贵宝公司 |
The pyridine compounds of the triazole substitution as kinase inhibitor
|
ES2575604T3
(en)
|
2012-01-13 |
2016-06-29 |
Bristol-Myers Squibb Company |
Thiazolyl or thiadiazolyl substituted pyridyl compounds useful as kinase inhibitors
|
WO2013106612A1
(en)
*
|
2012-01-13 |
2013-07-18 |
Bristol-Myers Squibb Company |
Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
|
JP6114317B2
(en)
|
2012-02-24 |
2017-04-12 |
シグナル ファーマシューティカルズ,エルエルシー |
Method of treating non-small cell lung cancer using combination therapy of TOR kinase inhibitors
|
EP2831080B1
(en)
|
2012-03-29 |
2017-03-15 |
Francis Xavier Tavares |
Lactam kinase inhibitors
|
CN103930425B
(en)
*
|
2012-05-14 |
2016-04-27 |
华东理工大学 |
Pteridinone derivative and the application as EGFR, BLK, FLT3 inhibitor thereof
|
GB201209609D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
GB201209613D0
(en)
|
2012-05-30 |
2012-07-11 |
Astex Therapeutics Ltd |
New compounds
|
EP2861595B9
(en)
|
2012-06-13 |
2017-06-21 |
Incyte Holdings Corporation |
Substituted tricyclic compounds as fgfr inhibitors
|
WO2014026125A1
(en)
|
2012-08-10 |
2014-02-13 |
Incyte Corporation |
Pyrazine derivatives as fgfr inhibitors
|
GB201216018D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Pharmacologically active compounds
|
GB201216017D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
WO2014052365A1
(en)
|
2012-09-26 |
2014-04-03 |
Mannkind Corporation |
Multiple kinase pathway inhibitors
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
CN104781251B
(en)
*
|
2012-11-08 |
2016-12-14 |
百时美施贵宝公司 |
Can as kinase modulator through the substituted pyridinyl compounds of bicyclic heterocycle
|
CN104781254B
(en)
|
2012-11-08 |
2016-12-14 |
百时美施贵宝公司 |
Can as kinase modulator through the substituted pyridinyl compounds of heteroaryl
|
WO2014089913A1
(en)
*
|
2012-12-12 |
2014-06-19 |
山东亨利医药科技有限责任公司 |
Bicyclic compound functioning as tyrosine kinase inhibitor
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
PE20151995A1
(en)
|
2013-01-16 |
2016-01-13 |
Signal Pharm Llc |
Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
CA2906166A1
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Hspc-sparing treatments for rb-positive abnormal cellular proliferation
|
US20160052926A1
(en)
*
|
2013-03-15 |
2016-02-25 |
Hutchison Medipharma Limited |
Novel pyrimidine and pyridine compounds and usage thereof
|
US9630966B2
(en)
|
2013-04-17 |
2017-04-25 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
UA115805C2
(en)
|
2013-04-17 |
2017-12-26 |
Сігнал Фармасьютікалз, Елелсі |
Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
|
AU2014254059B2
(en)
|
2013-04-17 |
2019-06-06 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a TOR kinase inhibitor and a cytidine analog for treating cancer
|
EP2986322A1
(en)
|
2013-04-17 |
2016-02-24 |
Signal Pharmaceuticals, LLC |
Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
|
NZ730189A
(en)
|
2013-04-17 |
2018-09-28 |
Signal Pharm Llc |
Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
|
JP2016516818A
(en)
|
2013-04-17 |
2016-06-09 |
シグナル ファーマシューティカルズ,エルエルシー |
Combination therapy comprising a TOR kinase inhibitor and N- (3- (5-fluoro-2- (4- (2-methoxyethoxy) phenylamino) pyrimidin-4-ylamino) phenyl) acrylamide for the treatment of cancer
|
EP2986298A1
(en)
|
2013-04-17 |
2016-02-24 |
Signal Pharmaceuticals, LLC |
Treatment of cancer with dihydropyrazino-pyrazines
|
DK2986610T5
(en)
|
2013-04-19 |
2018-12-10 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
GB201307577D0
(en)
|
2013-04-26 |
2013-06-12 |
Astex Therapeutics Ltd |
New compounds
|
US9604939B2
(en)
|
2013-05-29 |
2017-03-28 |
Signal Pharmaceuticals, Llc |
Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use
|
AR099376A1
(en)
|
2013-12-20 |
2016-07-20 |
Signal Pharm Llc |
Diaminopirimidilo substituted compounds, compositions and methods of treatment with these |
UY35935A
(en)
|
2014-01-03 |
2015-06-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Nicotinamide compounds heteroaryl substituted as kinase inhibitors and modulators of IRAK-4 |
EP3099672A4
(en)
|
2014-01-31 |
2017-09-20 |
ONO Pharmaceutical Co., Ltd. |
Fused imidazole compounds
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
WO2015144804A1
(en)
|
2014-03-26 |
2015-10-01 |
Astex Therapeutics Ltd |
Combinations
|
TW201613901A
(en)
|
2014-03-26 |
2016-04-16 |
Astex Therapeutics Ltd |
New compounds
|
NZ629860A
(en)
|
2014-04-16 |
2016-01-29 |
Signal Pharm Llc |
Methods for treating cancer using tor kinase inhibitor combination therapy
|
NZ629866A
(en)
|
2014-04-16 |
2015-12-24 |
Signal Pharm Llc |
Solid forms comprising 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, and a coformer, compositions and methods of use thereof
|
NZ629884A
(en)
|
2014-04-16 |
2016-03-31 |
Signal Pharm Llc |
Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, and a coformer, compositions and methods of use thereof
|
NZ714742A
(en)
|
2014-04-16 |
2017-04-28 |
Signal Pharm Llc |
Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
|
WO2015161285A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
|
NZ629796A
(en)
|
2014-07-14 |
2015-12-24 |
Signal Pharm Llc |
Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
|
EA201790189A1
(en)
|
2014-07-14 |
2017-11-30 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Methods of treating malignant numer formation using substituted pyrropyrymidin compounds, compositions on their basis
|
CN105294681B
(en)
|
2014-07-26 |
2017-07-07 |
广东东阳光药业有限公司 |
Compound of CDK type small molecular inhibitors and application thereof
|
EP3191098A4
(en)
|
2014-09-12 |
2018-04-25 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
CN105622638B
(en)
*
|
2014-10-29 |
2018-10-02 |
广州必贝特医药技术有限公司 |
Pyrimidine or pyridopyridine ketone compounds and its preparation method and application
|
CN104447743B
(en)
*
|
2014-11-26 |
2016-03-02 |
苏州明锐医药科技有限公司 |
Paboxini preparation |
CN104496983B
(en)
*
|
2014-11-26 |
2016-06-08 |
苏州明锐医药科技有限公司 |
A kind of preparation method of Pa Boxini
|
EA201791867A1
(en)
|
2015-02-20 |
2017-12-29 |
Инсайт Корпорейшн |
Bicyclic heterocycles as fgfr4 inhibitors
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
MX2017010673A
(en)
|
2015-02-20 |
2018-03-21 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors.
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
CN106146515A
(en)
*
|
2015-04-17 |
2016-11-23 |
常州隆赛医药科技有限公司 |
The preparation of Azaindole kinase inhibitors and application
|
EP3313844A1
(en)
|
2015-06-24 |
2018-05-02 |
Bristol-Myers Squibb Company |
Heteroaryl substituted aminopyridine compounds
|
JP2018522859A
(en)
|
2015-06-24 |
2018-08-16 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Heteroaryl-substituted aminopyridine compounds
|
MX2018001004A
(en)
|
2015-07-24 |
2018-06-07 |
Celgene Corp |
Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein.
|
US20170129902A1
(en)
|
2015-10-16 |
2017-05-11 |
Abbvie Inc. |
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-alpha]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
|
KR20190025943A
(en)
*
|
2016-07-01 |
2019-03-12 |
쥐원 쎄라퓨틱스, 인크. |
Pyrimidine-based antiproliferative agents
|
WO2018097295A1
(en)
*
|
2016-11-28 |
2018-05-31 |
帝人ファーマ株式会社 |
Crystal of pyrido[3, 4-d]pyrimidine derivative or solvate thereof
|